Monday, October 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 28, 2025

GE HealthCare CEO Peter Arduini is forging a new chapter for the $20 billion-a-year business while drawing on Jack Welch’s legacy

View original at finance.yahoo.com
GE HealthCare CEO Peter Arduini is forging a new chapter for the $20 billion-a-year business while drawing on Jack Welch’s legacy On Jan. 4, 2023, GE HealthCare Technologies (No…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • GE HealthCare stock is up almost 50% since IPO on January 4, 2023

    80% confidence

  • Authenticity and direct communication are critical for CEOs in today's world with younger employee base and social media

    80% confidence

  • Harmony between China and the U.S. is beneficial for the world and necessary for GE HealthCare to reach full potential

    80% confidence

  • GE HealthCare reduced China imports from 75% to now making 85-90% of products locally for the China market

    80% confidence

  • China will eventually become the largest healthcare market with 1.4 billion people

    80% confidence

  • As a standalone company, GE HealthCare can make decisions faster with better focus and less noise

    80% confidence

  • Med tech is an American gem with 70%+ of products made in the United States and majority of IP originating there

    80% confidence

  • GE gave employees bold assignments at a very young age and had a tough but fair culture under Jack Welch

    80% confidence

  • R&D investment doubled from $750-800 million in 2018 to over $1.4 billion currently

    80% confidence

  • Innovation requires a 3 to 5 year cycle in the medical technology business

    80% confidence

  • Larry Culp characterized himself as a down-to-earth, focused, and intentional leader

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
GE HealthCare CEO Peter Arduini is forging a new chapter for the $20 billion-a-year business while drawing on Jack Welch’s legacy — Source | Via News | ViaNews Market